April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Ozurdex Outcomes in Retinal Vein Occlusion (RVO) with Macular Oedema (MO)
Author Affiliations & Notes
  • Valerie Juniat
    Kent & Canterbury Hospital, Canterbury, United Kingdom
  • Eleni Tsolakou
    Kent & Canterbury Hospital, Canterbury, United Kingdom
  • Nishal Patel
    Kent & Canterbury Hospital, Canterbury, United Kingdom
  • Footnotes
    Commercial Relationships Valerie Juniat, None; Eleni Tsolakou, None; Nishal Patel, Allergan (F), Allergan (R), Bayer (S), Novartis (F), Novartis (R), ThromboGenics (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3890. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valerie Juniat, Eleni Tsolakou, Nishal Patel; Ozurdex Outcomes in Retinal Vein Occlusion (RVO) with Macular Oedema (MO). Invest. Ophthalmol. Vis. Sci. 2014;55(13):3890.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Ozurdex is a biodegradeable intravitreal steroid implant that is currently approved for treatment of patients with MO due to RVO in the UK. This retrospective study aimed to evaluate the visual outcomes, anatomical outcomes, and complications in patients treated with Ozurdex for MO secondary to RVO.

Methods: Data was collected using Medisoft and Topcon OCT imaging. Data was analysed using Microsoft Excel and statistical analysis was carried out using Medcalc software.

Results: 182 Ozurdex implants were carried out over 15 months between 2012 and 2013. 115 procedures were included in the audit. 6% were lost to follow up. The median time interval between diagnosis and first treatment was 11 months (range 1 to 67 months). The average time interval between pre-treatment baseline visual acuity (VA) and post-treatment final VA was 6 months (range 2 to 19 months). Mean difference in VA post-treatment was -0.08 (Logmar). OCT analysis showed average central retinal thickness (CRT) reduction of 159μm post-treatment. Complications included cataract formation (4.4%) and raised intraocular pressure >35mmHg (4.3%). 3.4% patients converted into ischaemic vein occlusion.

Conclusions: Ozurdex is currently approved for use in patients with MO due to RVO in the UK irrespective of their baseline visual acuity. This audit demonstrated that Ozurdex implantations achieved anatomical improvement in patients with MO secondary to RVO that did not correlate with visual improvement. VA improvement occurred mostly in patients with severe reduction of acuity at onset, indicating effectivity post reduction of macular oedema. Poor baseline visual acuity and existing co-pathology in these patients could have contributed towards lack of visual improvement. Non-improvement of acuity post Ozurdex treatment associated with a dry macula is likely to be associated with poor anti-VEGF therapy response, however all patients with recurrent oedema should be offered retreatment with either agent in RVO.

Keywords: 688 retina • 462 clinical (human) or epidemiologic studies: outcomes/complications  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.